Vertex Pharmaceuticals Incorporated / Fundamentals
Income statement
- Net revenue
€9.74B - Cost of goods sold
€1.35B - Gross profit
€8.39B - SG&A expenses
€1.34B - R&D expenses
€3.27B - EBITDA
€3.99B - D&A
€241.98M - EBIT
€3.35B - Interest expenses
€14.50M - EBT
€3.73B - Tax expenses
€628.11M - Net income
€3.10B
Cash flow statement
- Net deferred tax
-€321.65M - Non-cash items
€468.53M - Changes in working capital
-€724.16M - Operating cash flow
€3.28B - Capex
€295.72M - Other investing cash flow
-€261.51M - Net investing cash flow
-€1.46B - Total cash dividends paid
€0.00 - Issuance of common stock
€21.41M - Debt repayment
-€7.93M - Other financing cash flow
€16.80M - Net financing cash flow
-€1.54B - Foreign exchange effects
€53.91M - Net change in cash
€342.80M - Cash at end of period
€4.25B - Free cash flow
€3.58B
Balance sheet
- Cash and cash equivalents
€4.24B - Cash and short-term investments
€5.44B - Total receivables
€1.62B - Inventory
€1.28B - Other current assets
€556.38M - Total current assets
€8.89B - Property, plant & equipment
€2.26B - Goodwill
€1.30B - Intangible assets
€371.46M - Long-term investments
€4.82B - Other non-current assets
€920.16M - Total non-current assets
€11.61B - Total assets
€20.50B - Accounts payable
€3.17B - Short-term debt
€0.00 - Other current liabilities
€362.85M - Total current liabilities
€3.53B - Long-term debt
€1.30B - Deferred tax liabilities
€0.00 - Other non-current liabilities
€1.02B - Total non-current liabilities
€2.32B - Total liabilities
€5.85B - Common stock
€218.61M - Retained earnings
€14.43B - Other equity
-€86.23M - Total equity
€14.65B - Total liabilities and shareholders' equity
€20.50B
Company information
- Market capitalization
€96.66B - Employees
6.1K - Enterprise Value
€113.16B
Company ratios
- Gross margin
-
86.1% Much better than peer group: -6,037.3% - EBITDA margin
-
40.9% Much better than peer group: -8,608.7% - EBIT margin
-
34.4% Much better than peer group: -8,674.2% - EBT margin
-
38.3% Much better than peer group: -28,101.7% - Net margin
-
31.9% Much better than peer group: -10,097.5% - ROE
-
21.2% Much better than peer group: -77.7% - ROA
-
15.1% Much better than peer group: -31.4% - Asset turnover
-
47.5% Much better than peer group: 21.4% - FCF margin
-
30.6% Much better than peer group: -6,772.4% - FCF yield
3.1% - Efficiency ratio
59.1% - Net sales per employee
-
€1.60M - Net income per employee
-
€508.64K